ISSN 1671-5411 CN 11-5329/R
Online Office
Author
Editor-in-Chief
Reviewer
Editor
Current Issue
EDITORIAL
Rotor hypothesis in the time chain of atrial fibrillation
Chang-Hao XU, Xu LIU
2022, 19(4): 251-253.   doi: 10.11909/j.issn.1671-5411.2022.04.010
Abstract(0) FullText HTML(0) PDF (0)
RESEARCH ARTICLE
Ambulatory diastolic blood pressure: a marker of comorbidity in elderly fit hypertensive individuals?
Alfredo De Giorgi, Rosaria Cappadona, Caterina Savriè, Benedetta Boari, Ruana Tiseo, Giulia Marta Viglione, Christian Molino, Elisa Misurati, Mauro Pasin, Roberto Manfredini, Fabio Fabbian
2022, 19(4): 254-264.   doi: 10.11909/j.issn.1671-5411.2022.04.009
Abstract(24) FullText HTML(9) PDF (3)
Essen score in the prediction of cerebrovascular events compared with cardiovascular events after ischaemic stroke or transient ischaemic attack: a nationwide registry analysis
Long LI, Ze-Ning JIN, Yue-Song PAN, Jing JING, Xia MENG, Yong JIANG, Hao LI, Cai-Xia GUO, Yong-Jun WANG
2022, 19(4): 265-275.   doi: 10.11909/j.issn.1671-5411.2022.04.002
Abstract(73) FullText HTML(30) PDF (3)
Pre-hospital delay in patients with acute myocardial infarction in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project
Dan-Qing HU, Yong-Chen HAO, Jun LIU, Na YANG, Yi-Qian YANG, Zhao-Qing SUN, Dong ZHAO, Jing LIU
2022, 19(4): 276-283.   doi: 10.11909/j.issn.1671-5411.2022.04.005
Abstract(7) FullText HTML(3) PDF (1)
Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study
Li-Jun LIU, Guo-Hua ZHU, Hong-Yu LUO, Xi-Peng SUN, Jing LI, Qi HUA
2022, 19(4): 284-291.   doi: 10.11909/j.issn.1671-5411.2022.04.008
Abstract(3) FullText HTML(1) PDF (0)
Trends and sex differences in atrial fibrillation hospitalization and catheter ablation at tertiary hospitals in China from 2013 to 2016
Kang LI, Fang-Fang FAN, Peng-Fei SUN, Jie JIANG, Jing ZHOU, Ying SHI, Hai-Bo WANG, Jian-Ping LI, Yan ZHANG, Yong HUO
2022, 19(4): 292-300.   doi: 10.11909/j.issn.1671-5411.2022.04.006
Abstract(1) FullText HTML(0) PDF (0)
Implication of a novel truncating mutation in titin as a cause of autosomal dominant left ventricular noncompaction
Xue-Qi DONG, Di ZHANG, Yi QU, Yu-Xiao HU, Chun-Xue YANG, Tao TIAN, Nan XU, Hai-Lun JIANG, Li ZENG, Peng-Yan XIA, Ya-Xin LIU, Rui LIU, Xian-Liang ZHOU
2022, 19(4): 301-314.   doi: 10.11909/j.issn.1671-5411.2022.04.001
Abstract(1) FullText HTML(0) PDF (0)
LETTER TO THE EDITOR
Invasive versus non-invasive hemodynamic monitoring of heart failure patients and their outcomes
Fadi Kandah, Pooja Dhruva, Raj Shukla, Maedeh Ganji, Carlos Palacio, Emil Missov, Jose Ruiz-Morales
2022, 19(4): 315-318.   doi: 10.11909/j.issn.1671-5411.2022.04.004
Abstract(1) FullText HTML(0) PDF (0)
New-onset heart failure masking a massive retroperitoneal liposarcoma
Jose Rivas Rios, Yi-Xin ZHANG, Melissa Oye, Civan Altunkaynak, Jinous Saremian, Emil Missov
2022, 19(4): 319-321.   doi: 10.11909/j.issn.1671-5411.2022.04.003
Abstract(1) FullText HTML(0) PDF (0)
3D vena contracta area in degenerative mitral regurgitation: cross-platform comparison in a single patient
Shing Ching, Chiu Sun Yue
2022, 19(4): 322-324.   doi: 10.11909/j.issn.1671-5411.2022.04.007
Abstract(0) FullText HTML(0) PDF (0)
Online First
Si-Yu YAN, Wei-Xian YANG, Pei-Pei LU, Xuan-Tong GUO, Cai-Xia GUO, Yan-Ni SU, Li-Hong MA
 doi: 10.11909/j.issn.1671-5411.2022.04.011
Abstract(52) FullText HTML(17) PDF (3)
Abstract:
 BACKGROUND Chinese herbal medicine is widely used as a complement or alternative treatment in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in China. We compared the incidence of the major adverse cardiovascular event (MACE) of CAD patients with or without the complement use of Chinese herbal medicine after PCI. METHODS In this prospective, observational study that was conducted from September 2016 to August 2019 in Fuwai Hospital, China, we followed up consecutive patients who received PCI treatment for 2 years. MACE was defined as the composite all-cause mortality, revascularization, and myocardial infarction (MI) and was compared between those using (integrative medicine group) or those not using Chinese herbal medicine as an additional treatment to standard western medicine (western medicine group), with unadjusted (Kaplan-Meier curves) and risk-adjusted (multivariable Cox regression) analyses. RESULTS A total of 5942 patients after PCI were enrolled in this study, and 5453 patients were included in the final analysis (4189 [76.8%] were male; mean [SD] age, 61.9 [9.9%] years). During the follow-ups, 2932 (53.8%) patients used only western medicine while 2521(46.2%) patients had used Chinese herbal medicine as an additional treatment to standard western medicine. Patients in the integrative medicine group (IM group) were older than the western medicine group (WM group), had more females and less previous MI. The incidence of MACE was 15.3% (449/2932) in WM group and 11.54% (291/2521) in IM group. Cox regression analysis showed that cumulative incidence of MACE was 27% lower in patients of the IM group than those in WM group (hazard ratio [HR], 0.73; 95% CI, 0.63-0.85; P<0.0001). CONCLUSIONS For CAD patients after PCI treatment, complement use of Chinese herbal medicine is associated with a lower 2-year MACE incidence. Randomized prospective studies are warranted to provide higher levels of benefit evidence in these patients.
Latest News
We would delightedly report that the 2020 SCI impact factor of Journal of Geriatric Cardiology(JGC,ISSN 1671-5411/ CN 11-5329/R) has increased from 2.491 to 3.327, according to the 2020 Journal Citation Reports (InCites, Clarivate Analytics), ranking 33/53 and 65/142 in the fields of Geriatrics & Gerontology and Cardiac & Cardiovascular Systems, respectively. Show more
Press releases Press office Contact us